Luterbach/Cambridge - The US biotech firm Biogen has received approval for its Alzheimer’s drug Leqembi in the USA. This means that production activities in Luterbach in the canton of Solothurn can now get under way. The drug will initially be exclusively manufactured in Switzerland.

At the start of July, Biogen received the definitive approval in the USA for its Alzheimer’s drug Leqembi, further details of which can be found in the company’s press release. It is the first Alzheimer’s drug of its kind to receive traditional approval. It is intended to eliminate stuck proteins in the brains of patients and should work against both symptoms and causes of the disease overall. 

With the approval of the drug, production activities at Biogen’s site in Luterbach in the canton of Solothurn can now commence. The drug will initially be manufactured exclusively at this location. Biogen has invested around 1.5 billion Swiss francs in its Luterbach plant, which offers space for more than 500 employees. 

Biogen developed its Alzheimer’s drug in conjunction with the Japanese pharma firm Eisai. A predecessor drug by the name of Aduhelm was ultimately shelved, Neurimmune from Schlieren in the canton of Zurich had also collaborated on the development of this drug. ce/ssp

Meet with an expansion expert

Our services are free of charge and include:

  • Introduction to key contacts in industry, academia, and government
  • Advice on regulatory framework, taxes, labor, market, and setting up a company
  • Custom-made fact-finding visits, including office and co-working space